India Glycols has successfully demerged, creating three independent entities and allowing the parent company to sharpen its focus on bio-based specialty materials, sustainable performance chemicals, and gases.

Post-demerger, the retained business reported FY26 net sales of ₹1,164 Cr, a decline from FY24's ₹1,581 Cr.

However, Adjusted EBITDA significantly grew to ₹330 Cr in FY26 from ₹247 Cr in FY24, with margins improving sharply from 15.6% to 28.4%. This highlights strong operating leverage and a focus on high-quality business.

Key segments like Bio-Glycols (₹325 Cr sales), Bio-Glycol Ethers (₹221 Cr sales), Performance Chemicals (₹56 Cr sales), and a strong Clariant IGL JV (₹419 Cr sales to JV) drive performance.

IGL holds unique positions as the sole manufacturer of Bio-Ethylene Glycols and Bio-Glycol Ethers, and the world's first in Bio-based Amines.

Management envisions ambitious growth: 10x sales and profits over the next decade, with targets of ₹2,000 Cr net revenue and ₹400 Cr EBITDA in 4-5 years.

The strategy centers on scaling specialty chemistries, expanding into global markets, and capitalizing on the growing demand for sustainable, lower-carbon alternatives, leveraging 97% renewable raw materials.